Vinflunine: The Latest Advance in Mesothelioma Treatment

Research hospitals in Europe have successfully tested a new anticancer drug, “Vinflunine” (pronounced VIN-floo-neen). The October 20th issue of Journal of Clinical Oncology featured the news that Vinflunine has been shown to improve response and survival rates in patients diagnosed with malignant pleural mesothelioma, according to Reuters.

Vinflunine was recently tested in Phase II clinical trials at hospital research centers in England and France. Dr. Talbot, from the Churchill Hospital in Oxford, and medical colleagues at seven European hospital centers, assessed the response rates of 67 patients who had not received prior chemotherapy or radiotherapy to determine the effectiveness of first-line Vinflunine treatment.

Doctors concluded that Vinflunine, when administered approximately every 21 days in high doses, improved patients’ response rates by 13.8 percent, and demonstrated such positive results that the drug therapy warrants further evaluation.

In 2004, the Food and Drug Administration (FDA) approved the first drug for this condition, “Alimta,” which, when used in combination with cisplatin, has helped patients extend their lives by several months, according to the FDA.

The National Cancer Institute reports that 2,000 cases of mesothelioma are diagnosed in the United States every year. The disease is often linked to industrial workplace exposure to asbestos, and is usually contracted through employers’ disregard for worker health safety.

Weitz & Luxenberg is a leading plaintiffs' law firm that has represented people affected by mesothelioma for over 20 years. Men and women diagnosed with mesothelioma or lung cancer caused by asbestos exposure may be entitled to compensation from the companies responsible for their disease. If you would like a free consultation or more information about your legal options, please complete the form below, and a representative of our law firm will contact you as soon as possible.